pharmaphorum March 4, 2024
AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation powers has stumbled at the first hurdle in a federal court.
US judge Colm Connolly of US district court in Delaware rejected AZ’s challenge just before the deadline for manufacturers to respond to Medicare’s initial price offers for the first 10 drugs selected for negotiation, which include AZ’s big-selling diabetes, heart failure, and chronic kidney disease therapy Farxiga (dapagliflozin).
The decision is an early win for the Biden administration in its defense of a series of lawsuits brought by pharma companies and other interested parties, which claim that allowing Medicare to negotiate prices is unconstitutional and violates administrative procedures.
Under the Inflation Reduction Act of 2022, the Department of Health and Human...
Today's Sponsors
Today's Sponsor